US Stock MarketDetailed Quotes
VERU Veru Inc
- 0.738
- +0.086+13.15%
Close Jan 3 16:00 ET
- 0.702
- -0.035-4.80%
Post 20:01 ET
107.96MMarket Cap-2.63P/E (TTM)
0.771High0.654Low2.74MVolume0.656Open0.652Pre Close2.01MTurnover2.33%Turnover RatioLossP/E (Static)146.38MShares1.92052wk High3.34P/B86.93MFloat Cap0.36052wk Low--Dividend TTM117.87MShs Float24.570Historical High--Div YieldTTM17.98%Amplitude0.271Historical Low0.733Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Veru Inc Stock Forum
👀
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Veru Inc. presented a meta-analysis of enobosarm's effects on body composition in older obese patients at ObesityWeek 2024. The analysis, based on four previous clinical trials, showed that enobosarm 3mg treatment led to better outcomes compared to placebo. By Day 147, enobosarm-treated subjects showed greater...
Veru Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.6%)
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
Veru Inc. (NASDAQ: VERU) announced its participation in the World Obesity and Weight Management Congress, scheduled for October 24-26, 2024, in Baltimore, Maryland. The company will deliver a keynote presentation on October 25, 2024, f...
and 102 000 share to FISCH HARRY
Veru Reports Fiscal 2024 Second Quarter Financial Results and
Progress of its Enobosarm High Quality Weight Loss Clinical Program
—Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for highquality weight loss is actively enrolling—
—Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDswith significant relevant medical, clinical and scientific expertise—
—Company to present this month at upcoming American Ass...
No comment yet